Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a clinical stage biotechnology company that regularly issues news and updates related to its focus on IL-1β-based treatments for immune-mediated inflammatory diseases. Company press releases consistently highlight progress with its lead asset, AVTX-009, a humanized monoclonal antibody targeting interleukin-1β (IL-1β), and its development in hidradenitis suppurativa (HS).
On this news page, readers can follow Avalo’s clinical development milestones, such as the design and execution of the Phase 2 LOTUS trial in adults with moderate to severe HS, completion of trial enrollment, and plans for future data readouts. The company’s releases describe the LOTUS trial as a randomized, double-blind, placebo-controlled Phase 2 study evaluating two AVTX-009 dosing regimens versus placebo, with HiSCR75 at Week 16 as the primary endpoint and several secondary HS disease activity and pain measures.
Avalo’s news flow also includes corporate and governance updates, including appointments of new board members and senior executives with backgrounds in clinical development, regulatory strategy, business development, finance and human resources. These announcements often describe related equity inducement grants and compensation arrangements, reflecting how the company structures incentives around its development priorities.
Investors and followers of AVTX can also find financial and capital markets communications in the company’s news, such as quarterly financial results summaries, cash runway commentary, and notices of participation in healthcare and biotechnology investor conferences. These items are frequently cross-referenced in Avalo’s Form 8-K filings, providing an official record of material events.
By reviewing Avalo Therapeutics news, readers gain insight into how the company is advancing AVTX-009 in hidradenitis suppurativa, how it frames the scientific rationale for IL-1β inhibition in immune-mediated inflammatory diseases, and how it is building its leadership and capital markets presence around this development strategy.
Avalo Therapeutics has entered into a worldwide exclusive license agreement with Apollo Therapeutics for AVTX-007, its IL-18 monoclonal antibody. Avalo will receive an upfront payment of approximately $15 million, including $5 million upon agreement execution and $10 million for transfer activities. Apollo will also pay up to $74 million in milestone payments and a small royalty on sales. This agreement will enable Avalo to extend its cash runway and concentrate on its lead molecule, AVTX-002, while transferring clinical development responsibilities to Apollo.
Avalo Therapeutics (Nasdaq: AVTX) announced a one-for-twelve reverse stock split effective July 7, 2022. This move aims to increase the stock price to meet Nasdaq Capital Market listing requirements. Following the split, shares outstanding will decrease from approximately 112.9 million to around 9.4 million. The reverse split will not affect the ownership percentage of stockholders, except those with fractional shares, who will receive whole shares. The company's stock will begin trading on a split-adjusted basis on July 8, 2022.
Avalo Therapeutics (Nasdaq: AVTX) announced that CEO Garry A. Neil will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 4:00 PM ET in New York. A live webcast will be available on the Company's website, and a replay will last for 90 days. Avalo Therapeutics focuses on precision medicine, aiming to develop targeted therapeutics for immunology and rare genetic diseases. Their clinical candidates are backed by proven mechanisms and established proof-of-concept to enhance success probability.
Avalo Therapeutics announced the dosing of the first patient in its Phase 2 PEAK trial, investigating AVTX-002 for non-eosinophilic asthma treatment. This randomized, double-blind, placebo-controlled study involves around 80 participants and focuses on the safety and efficacy of AVTX-002 over 12 weeks. The primary endpoint evaluates asthma-related events in patients. With nearly half of asthma patients affected by non-eosinophilic asthma, this trial could address a significant unmet medical need in asthma treatment.
Avalo Therapeutics (Nasdaq: AVTX) will have its CEO, Garry A. Neil, present virtually at the H.C. Wainwright Global Life Sciences Conference from May 23-26, 2022. The pre-recorded presentation will be available on May 24, 2022, at 7:00 AM ET. Investors can access the webcast on the company's website under the 'News/Events' section. Avalo is focused on developing targeted therapeutics for significant unmet clinical needs, particularly in immunology and rare genetic diseases, with a diverse portfolio aimed at delivering meaningful medical impact.
Avalo Therapeutics (AVTX) announced significant updates including the initiation of Phase 2 clinical trials for AVTX-002 in non-eosinophilic asthma and AVTX-803 for leukocyte adhesion deficiency type II. The company executed a workforce reduction of approximately one third to align with pipeline prioritization, aiming to reduce expenses over time. As of March 31, 2022, Avalo reported cash and cash equivalents of $38 million, a decrease driven primarily by operating expenses. The net loss for Q1 2022 was $22.1 million, reflecting continued investment in pipeline development.
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage precision medicine company, announced participation at Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022, at 1:20 p.m. ET. The event will showcase Avalo's innovative therapies, focusing on unmet clinical needs in immunology and rare genetic diseases. A live webcast will be available on their website. Avalo emphasizes its commitment to developing targeted therapeutics, and the potential impact of its portfolio aimed at enhancing patient care.
Avalo Therapeutics (AVTX) announced key updates, including the promotion of Dr. Garry Neil to CEO and Chris Sullivan to CFO. The company plans to initiate a Phase 2 trial for AVTX-002 targeting moderate to severe Non-eosinophilic Asthma, with topline data expected in Q4 2022. As of December 31, 2021, Avalo reported cash and equivalents of $54.6 million, a $35.7 million increase from 2020, driven by public offerings and debt facilities. However, total operating expenses rose by $8 million, primarily due to R&D costs.
Avalo Therapeutics has announced a leadership transition with Dr. Garry Neil appointed as Chief Executive Officer, effective February 14, 2022. Chris Sullivan has been promoted to Chief Financial Officer. The previous CEO and CFO, Mike Cola and Schond Greenway, respectively, have stepped down. The Board expressed appreciation for their contributions while highlighting the firm's promising future, particularly with the development of AVTX-002 for inflammatory diseases. Both Neil and Sullivan bring extensive experience to their new roles, aiming to enhance operational success and shareholder value.
Avalo Therapeutics, a clinical-stage precision medicine company (Nasdaq: AVTX), announced participation at the 2022 BIO CEO and Investor Conference, taking place in New York City from February 14-15 and virtually until February 17, 2022. The senior management team will present and hold 1x1 meetings, with a pre-recorded presentation available from February 11, 2022, for registered attendees. Avalo focuses on developing targeted therapeutics for unmet clinical needs in immunology and rare genetic diseases, aiming to enhance patient outcomes through innovative therapies.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
